Vera Therapeutics Inc. (VERA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.
Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)
Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.
Vera Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 298,164 | $11.21M | $9.32M | -$1.88M | -16.8% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.21M | $45.25M | $37.86M | -$7.39M | -16.33% |
| CCP Christopher C. Powers Farther Finance Advisors, LLC | 28 | $1,202.57 | $875.56 | -$327.01 | -27.19% |
| MC Mathieu Cornu Pictet Asset Management Holding SA | 1.05M | $32.51M | $32.88M | $369,966.1 | 1.14% |
| TPW Twin Peaks Wealth Advisors LLC TWIN PEAKS WEALTH ADVISORS, LLC | 2 | $80 | $62.54 | -$17.46 | -21.82% |
Vera Therapeutics Inc. (VERA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vera Therapeutics Inc. ever had a stock split?
Vera Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gary Barrera CEO | NASDAQ (NMS) Exchange | 92337R101 CUSIP |
| US Country | 152 Employees | 10 Jan 1996 Last Dividend | - Last Split | 14 May 2021 IPO Date |
Overview
Vera Therapeutics, Inc. is a clinical stage biotechnology firm based in the United States, with a specific focus on addressing serious immunological diseases. Initially founded under the name Trucode Gene Repair, Inc., the company underwent a name change to Vera Therapeutics, Inc. in April 2020. Since its incorporation in 2016, Vera Therapeutics has been headquartered in Brisbane, California, manifesting its commitment to innovation in the biopharmaceutical sector through its active development and commercialization efforts targeting unmet medical needs in immunology.
Products and Services
- Atacicept:
This leading product candidate of Vera Therapeutics is positioned as a groundbreaking fusion protein therapy, administered through subcutaneous injections. Currently, it is undergoing Phase IIb clinical trials, focusing on treating patients with immunoglobulin A nephropathy (IgAN). Atacicept aims to offer a new beacon of hope for patients suffering from this chronic autoimmune disease, potentially altering the course of treatment and improving patient outcomes substantially.
- MAU868:
Another promising candidate from Vera Therapeutics' portfolio is MAU868, a monoclonal antibody that is in Phase 2 clinical trials. This innovative therapy is designed for the treatment of BK viremia infections, a significant complication in transplant recipients that can result in the loss of the transplanted organ. By targeting the BK virus with precision, MAU868 has the potential to significantly reduce the incidence of transplant-related complications, offering a new lifeline to patients undergoing organ transplants.
